SCENAR

The Scenar device, is the latest incarnation of an electronic instrument developed by scientists working in the Russian aerospace industry, in the town of Taganrog, Russia. The name is an acronym derived from "Self Controlled Energo-Neuro-adaptive Regulation". It has, in earlier incarnations been known as the "Inter-X -5002". Prof. Dr. Alexander M. Revenko (neurology) is the founder of the company.

Description
The device is sold for the treatment of acute and chronic  pain, and is represented as being useful in solo therapy as well as in combination with other therapeutic modalities, as it "has  very few contraindications".

Scenar is represented as being capable of interaction with the nervous, immune and endocrine systems through a biofeedback mechanism. It is believed that it "ensures regulation of various mediators and neuropeptides". And, it main goal is the maintenance of homeostasis through interactions with the body's immune and hormonal systems.

History
In the beginning, there the SCENAR-035, or 'troika', as it is pronounced in Russian. The Grandmother of SCENARs. It was a good, reliable, stable, and effective model. Not very pretty on the outside, in a black rectangular case, yet nevertheless very functional. SCENAR-035 is known mostly just inside Russia, and some doctors work with it even now. In fact, those almost unbelievable SCENAR results reported by Dr. Yuri Gorfinkel and Dr Revenko in 1998 in his famous Summary of individual results (which appears all over the SCENAR literature) were obtained mostly with the SCENAR-035. This model was designed by Dr. Karasev and massively produced by OKB Ritm.

FDA Approvals
Scenar technology is, as of May, 2010, an FDA approved device, for treatment of pain, under the following class: DEVICE: SCENAR, MODEL 10, RITM OKB ZAO 510(k) NO: K092117(TRADITIONAL). It is cleared for the treatment and management of acute and chronic pain and the management of post-surgical and post-traumatic pain. It may be dispensed only upon the prescription of a licensed health care provider.

Scientific Research
Several studies have shown benefits in treatment of various conditions, most of which demonstrate results significantly greater than could be explained by placebo alone. Some studies the company provides were never published, but were performed at their request, however there are some rather interesting and positive results.

Enuresis

 * 1995 - V.A Lebedev (Physiotherapist), reported  in the journal Вопросы курортологии, физиотерапии и лечебной физкультуры  (Investigations in therapeutic spas, physiotherapy and therapeutic physical culture), that he "recommends a self-control energoneuroadaptive regulator (SCENAR) as effective in the treatment of neurogenic dysfunction of the bladder in children with nocturnal enuresis. This regulator operates according to the principles of Chinese medicine and may be used in sanatoria and at home by the children's parents specially trained by physiotherapist".

Pain

 * 2004 - Lopatina, A.B, reported in a Dissertation for her Doctorate in Education, that the Scenar had shown benefits in "speeding the recovery period in athletes".
 * 2005 - A study of 60 patients post trochanteric joint surgery, with the early model Scenar (InterX) device, run in Moscow, Russia and published in the Journal of Bone and Joint Surgery, Gorodetskiy et al, conclude that the scenar treated patients had significantly reduced pain as compared to the sham (placebo) or for the "non-invasive neuro-stimulation" groups..
 * 2006 - Presenting at the XVth International Congress on Sports rehabilitation and Traumatology, P. Massetti gave a case study of two young men, 6 months post contusion; one 24 years old, with tears of the femoris and medial vastus lateralis, after 7 treatments showed significant reduction in pain, and increased range-of-motion, and after one week of treatment, the symptoms "were completely  resolved" ; and the other 38 years old, with strain of the tibialis medius, interfering with his ability to participate in sports. His pain extended into the insertion of the Achilles tendon. His treatment was 2x week, together with CO2 laser and ultrasound. Following 10 applications of alternating laser+ultrasound and Scenar therapy the patient had a complete remission of symptoms.
 * 2006 - At the same Congress in which he gave his case report, Massetti  published a  paper in which he indicates having treated 20 patients, including both professional and amateur athletes with varying painful conditions. According to  his report, all of the patients, after 2 treatments, 2x/week demonstrated "significant reduction in symptoms" unexplainable as resulting from any other possible cause. Massetti concludes that the Scenar "is an instrument capable of drastically reducing the time of recuperation in significant traumatic events" ,
 * 2008 - Writing about his experiences at the European Speed Skating championships (Germany) and the subsequent World's in Spain, Rosario Bella, (a Physiotherapist) for the FIHP (Roller Hockey), in a report published at the medical site FCE news, of Scenar use together with kinesiotaping, states, that the "results were appreciable in noting the time of recuperation and eduction of symptoms to a tolerable level in a good percentage of the cases treated, even during the competition". And, that the SCENAR taken together with the taping provided a synergistic effect, then when taken alone.
 * 2010 - With results similar to their 2005 study, Gorodetskiy, et al, publishing in The Journal of Foot and Ankle Surgery in 2010, found results comparable to their earlier study, in patients post malleolar  (ankle joint) fracture surgery.

Post-herpetic neuralgia

 * 2007 - M.R. Ing, publishing in the Hawaii Medical Journal, treated three consecutive patients with post-herpetic neuralgia and found that ALL resolved their pain in no more than 5 sessions over a three week period.

Duodenal ulcer

 * 2006 - In a study published in Клиническая Медицина (Clinical medicine), Tsimmerman, et al, reported that 103 cases of duodenal ulcer were treated with Scenar alone and together with standard therapy for H pylori. They determined that "led to positive changes in most of the parameters under study", and "Addition of SCENAR therapy to the complex conventional pharmacotherapy [sic] 'sped up' ulcer healing, increased the effectiveness of Helicobacter pylori eradication, and improved the condition of the gastroduodenal mucosa".